HexemBio plans to advance its platform designed to rejuvenate aging blood stem cells, with an initial focus on improving bone marrow transplant outcomes in blood cancers.
This is part of J&J's $55B investment in US manufacturing over the next few years.
Zemcelpro (dorocubicel) is designed to support blood and immune system recovery after myeloablative conditioning in patients with hematologic diseases.
Zemcelpro® offers a new stem cell transplant option for adults with blood cancers unable to find compatible donors in Europe.
Calidi’s CLD-201, a novel stem cell-based oncolytic virus therapy, moves forward.
It's interesting to consider, much like with umbilical cords, how often are we incinerating life-saving stem cells?
The company plans on moving to Phase 2 later this year, hopefully supporting a BLA in the near future.
Allogene Therapeutics' dual-targeted CAR T therapy, ALLO-329, receives three FDA Fast Track designations, accelerating development for severe autoimmune conditions including lupus, myositis, and systemic sclerosis.
